Laplace Interventional Inc. Announces first close of an Oversubscribed Series B Financing of $12.9M for its Transcatheter Tricuspid Valve Technology
MINNEAPOLIS, July 24, 2023 /PRNewswire/ -- Minnesota based Laplace Interventional, a medical device company developing a transcatheter tricuspid valve technology, announced today that it has completed its first close on its Series B financing co-led by ShangBay Capital along with Features Capital, including participation from Engage Venture Partners, JWC Ventures as well as a global strategic investor. The $12.9M Series B financing will fund Laplace Interventional towards achieving its early clinical feasibility milestones. The company also announced that Jenny Barba, Co-Founder and Managing Partner at Features Capital, joined its Board of Directors and Todd Mortier, a serial MedTech entrepreneur had previously joined its Board of Directors.
- Laplace Interventional plans to use the funds raised from this round to pursue their First-in-Human (FIH) and clinical feasibility evaluation of its transcatheter valve system.
- The $12.9M Series B financing will fund Laplace Interventional towards achieving its early clinical feasibility milestones.
- Laplace Interventional's device is designed to offer an increase in life expectancy and an improvement to the quality of life to patients diagnosed with Tricuspid Regurgitation (TR).
- Laplace Interventional is developing a prosthetic valve that will be delivered through through patient vasculature not requiring an open-heart surgery and thereby reducing complications in patients.